Dry mouth as a novel indicator of hoarseness caused by inhalation therapy

Journal of Asthma

Volumn 52, Issue 3, 2015, Pages 296-300

  Hira, Daiki ^a,b   Koshiyama, Setsuko ^b,c   Komase, Yuko ^b,d   Hoshino, Nobuo ^a   Morita, Shin Ya ^a   Terada, Tomohiro ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^b Association of Inhalation Therapists   (Japan)

^c Access Life Co   (Japan)

^d ST MARIANNA UNIVERSITY   (Japan)

Author keywords

Adverse event; Fluticasone; Hyposalivation; Inhaled corticosteroids; Oral environment; Questionnaire

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG SAFETY; DRY POWDER INHALER; HOARSENESS; HUMAN; HYPOSALIVATION; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; METERED DOSE INHALER; OUTCOME ASSESSMENT; PREDICTION; QUESTIONNAIRE; SALIVATION; XEROSTOMIA; ADULT; AGED; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; HOARSENESS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SALIVATION; XEROSTOMIA;

EID: 84931029408     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2014.971965     Document Type: Article

References (23)

1. Dalby R, Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Deliv Rev 2003;55:779-791.
2. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991.
3. Kajiwara A, Kita A, Saruwatari J, Morita K, Oniki K, Yamamura M, Murase M, et al. Absence of gargling affects topical adverse symptoms caused by inhaled corticosteroids in females. J Asthma 2014;51:221-224.
4. Barnes NC. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 2007;16:149-154.
5. Fabbri L, Burge PS, Croonenborgh L, Warlies F, Weeke B, Ciaccia A, Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax 1993;48: 817-823.
6. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a metaanalysis. Ann Allergy Asthma Immunol 2007;98:225-238.
7. Ishizuka T, Hisada T, Aoki H, Yanagitani N, Kaira K, Utsugi M, Shimizu Y, et al. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma. Allergy Asthma Proc 2007;28:550-556.
8. Ayres JG, Bateman ED, Lundbäck B, Harris TA. High dose fluticasone propionate, 1mg daily, versus fluticasone propionate, 2mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. Eur Respir J 1995;8: 579-586.
9. Frois C, Wu EQ, Ray S, Colice GL. Inhaled corticosteroids or longacting beta-agonists alone or in fixed-dose combinations in asthma treatment: A systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther 2009;31:2779-2803.
10. Galván CA, Guarderas JC. Practical considerations for dysphonia caused by inhaled corticosteroids. Mayo Clin Proc 2012;87: 901-904.
11. Gerdin EW, Einarson S, Jonsson M, Aronsson K, Johansson I. Impact of dry mouth conditions on oral health-related quality of life in older people. Gerodontology 2005;22:219-226.
12. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007;96:644-647.
13. Molimard M, Le Gros V, Robinson P, Bourdeix I. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv 2010;23:91-95.
14. Lux R, Awa W, Walter U. An interdisciplinary analysis of sex and gender in relation to the pathogenesis of bronchial asthma. Respir Med 2009;103:637-649.
15. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-228.
16. Adams N, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007:CD002310.
17. Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice 2007;21:101-111.
18. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth, 2nd ed. Gerodontology 1997;14:33-47.
19. Hira D, Okuda T, Kito D, Ishizeki K, Okada T, Okamoto H. Inhalation performance of physically mixed dry powders evaluated with a simple simulator for human inspiratory flow patterns. Pharm Res 2010;27:2131-2140.
20. Yakubu SI, Assi KH, Chrystyn H. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: The influence of flow and volume. Int J Pharm 2013;455:213-218.
21. Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998;11:1111-1115.
22. Hira D, Okuda T, Ichihashi M, Mizutani A, Ishizeki K, Okada T, Okamoto H. Influence of peak inspiratory flow rates and pressure drops on inhalation performance of dry powder inhalers. Chem Pharm Bull (Tokyo) 2012;60:341-347.
23. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med 1993;6:99-110.